



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

BIB DATA SHEET

CONFIRMATION NO. 3995

SERIAL NUMBER	FILING or 371(c) DATE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO.	
10/502,180	07/21/2004	514	1612	OP/4-32328A	
RULE					
APPLICANTS Romulus Kimbro Brazzell, Alpharetta, GA; George N. Lambrou, Strasbourg, FRANCE; Elisabeth Latour, Bartenheim-La Chaussee, FRANCE; Anna Ottlecz, Basel, SWITZERLAND; Jeanette Marjorie Wood, Benken, SWITZERLAND;					
** CONTINUING DATA ***** This application is a 371 of PCT/EP03/00612 01/22/2003					
** FOREIGN APPLICATIONS ***** UNITED KINGDOM 0201520.4 01/23/2002					
** IF REQUIRED, FOREIGN FILING LICENSE GRANTED **					
Foreign Priority claimed <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No 35 USC 119(a-d) conditions met <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No Verified and <u>/GIGI GEORGIANA</u> <u>HUANG/</u> Acknowledged <u>Examiner's signature</u>	<input type="checkbox"/> Met after Allowance GH Initials	STATE OR COUNTRY GA	SHEETS DRAWINGS 0	TOTAL CLAIMS 12	INDEPENDENT CLAIMS 2
ADDRESS NOVARTIS CORPORATE INTELLECTUAL PROPERTY ONE HEALTH PLAZA 104/3 EAST HANOVER, NJ 07936-1080 UNITED STATES					
TITLE Pharmaceutical use of cox-2-inhibitors in angiogenesis-mediated ocular disorders					
FILING FEE RECEIVED 920	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:		<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees (Filing) <input type="checkbox"/> 1.17 Fees (Processing Ext. of time) <input type="checkbox"/> 1.18 Fees (Issue) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit		